Imugene Raises A$37.5m to Advance Off-the-Shelf CAR T Therapy with 75% Response Rate

• A$37.5 million capital raise via Placement and Share Purchase Plan
• Azer-cel Phase 1b trial reports 75% overall and 55% complete response rates
• Plans for pivotal Phase 2 registrational trial in 2026 targeting rare lymphomas
• Funding runway extended into mid-2027 with potential options exercise